Amanote Research
Register
Sign In
Lenalidomide Induced Stroke in Multiple Myeloma
Clinical Practice
- United Kingdom
doi 10.4172/clinical-practice.100093
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Pharmacology
Date
January 1, 2016
Authors
Shridhar P
Khalil R
Lasorda D
Chun Y
Publisher
OMICS Publishing Group
Related search
Proteasome Inhibitors Block Ikaros Degradation by Lenalidomide in Multiple Myeloma
Haematologica
Hematology
RNA Interference Screening Identifies Lenalidomide Sensitizers in Multiple Myeloma, Including RSK2
Blood
Biochemistry
Immunology
Cell Biology
Hematology
Update on the Role of Lenalidomide in Patients With Multiple Myeloma
Therapeutic Advances in Hematology
Hematology
GRP-024 Antithrombotic Prophylaxis in Patients With Multiple Myeloma Being Treated With Lenalidomide
European Journal of Hospital Pharmacy: Science and Practice
Pharmacy
Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone
Internal Medicine
Internal Medicine
Medicine
Efficacy of Carfilzomib, Lenalidomide, and Dexamethasone for Extramedullary Intracranial Localization of Multiple Myeloma
Case Reports in Hematology
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Lenalidomide Combined With Low-Dose Cyclophosphamide and Prednisone Modulates Ikaros and Aiolos in Lymphocytes, Resulting in Immunostimulatory Effects in Lenalidomide-Refractory Multiple Myeloma Patients
Oncotarget
Oncology
